Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer

BackgroundAnaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK+ NSCLC) is a model disease for use of targeted therapies (TKI), which are administered sequentially to maximize patient survival.MethodsWe retrospectively analyzed the flow of 145 consecutive TKI-treated ALK+ NSCLC patie...

Descrición completa

Detalles Bibliográficos

Principais autores:	Mei Elsayed, Farastuk Bozorgmehr, Daniel Kazdal, Anna-Lena Volckmar, Holger Sültmann, Jürgen R. Fischer, Mark Kriegsmann, Albrecht Stenzinger, Michael Thomas, Petros Christopoulos
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2021-04-01
Series:	Frontiers in Oncology
Assuntos:	ALK-rearranged non-small-cell lung cancer tyrosine kinase inhibitors chemotherapy sequential therapies overall survival
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fonc.2021.670483/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!